Download PDFPDF

TP021/#1540  Reframe-O1/ENGOT-OV79/GOG-3086: a phase 2/3 open-label study evaluating the efficacy and safety of luveltamab tazevibulin versus investigator’s choice chemotherapy in relapsed platinum-resistant EOC expressing folate receptor-alpha
Free
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address